The present invention relates to a pharmaceutical composition wherein the active substance comprises or consists in: -a protein comprising the sequence SEQ ID NO: 1, representing the APRIL protein, -or any derived protein, which is derived from protein of sequence SEQ ID NO: by substitution, removal or addition of one or more amino-acids, provided it allows the binding of the said derived protein to an astrocyte and/or CSPG, -or any homologous protein, the sequence of which has a percentage of identity of at least approximately 70 %, and in particular 85 % with said sequence SEQ ID NO: 1, provided it allows the binding of the said homologous protein to an 1 astrocyte and/or CSPG, or any fragment of the protein of sequence SEQ ID NO: 1, provided it allows the binding of the said fragment to an astrocyte and/or CSPG, in association with an acceptable pharmaceutical vehicle. 20 (no figures)
